Match the following clinical scenarios of terminally ill patients receiving end-of-life care with the most appropriate pharmacologic intervention for their symptoms.
- An 82-year-old actively dying man develops noisy, gurgling respirations due to the pooling of oropharyngeal secretions.Sublingual glycopyrrolate
- A 68-year-old woman with metastatic breast cancer experiences severe, distressing dyspnea at rest despite adequate oxygen saturation.Low-dose oral morphine
- A 74-year-old man with end-stage pancreatic cancer develops terminal delirium with severe agitation that is completely refractory to haloperidol.Continuous intravenous midazolam
- A 61-year-old woman with advanced ovarian cancer develops severe nausea and vomiting attributed to opioid-induced delayed gastric emptying.Oral metoclopramide
Answer
The correct pairings match each specific end-of-life symptom with its first-line evidence-based pharmacologic intervention: pooling secretions (death rattle) with glycopyrrolate, refractory dyspnea with morphine, refractory terminal delirium with midazolam, and opioid-induced gastroparesis with metoclopramide.
Each pairing correctly addresses the pathophysiology and standard palliative care guidelines for end-of-life symptoms: anticholinergics (glycopyrrolate) for secretions, opioids (morphine) for dyspnea, benzodiazepines (midazolam) for refractory delirium, and prokinetics (metoclopramide) for gastroparesis.
Step-by-Step Solution
Key Concept
Pharmacologic management of severe symptoms in end-of-life and palliative care.